While shares of Halozyme (HALO 0.34%) rose earlier this month on news that BMO Capital Markets had tripled its price target on the stock, it has now fallen back down 15% on very similar, but opposite, news. Wedbush lowered Halozyme from outperform to neutral, and cut its price target a bit. Jefferies has taken an even harsher, more bearish, stance. In this video, Motley Fool health-care analyst David Williamson takes us through some of the drugs in Halozyme's pipeline that have analysts either so up or so down on the stock, and tells us that one of these two sides is going to be very wrong about this company.
A Broken HALO for Wall Street?
By Dave Williamson – Jan 31, 2013 at 4:35PM
NASDAQ: HALO
Halozyme Therapeutics
Market Cap
$8.0B
Today's Change
(-0.34%) $0.23
Current Price
$68.01
Price as of November 10, 2025 at 4:00 PM ET
Who will win out on Halozyme -- the bulls or the bears?
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid